bioMerieux SA - Company Profile

Powered by

All the data and insights you need on bioMerieux SA in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date bioMerieux SA Strategy Report

  • Understand bioMerieux SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

bioMerieux SA: Overview

Select Item

Related keylists

bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures, and markets in vitro diagnostic solutions for hospital and private laboratories. The company offers diagnostic solutions such as systems, reagents and software for the diagnosis of infectious diseases, cardiovascular diseases and cancers, besides identifying microorganisms in pharmaceuticals, cosmetics, and agri-food products. It offers immunoassays, microbiology products, molecular biology tests, and other solutions for clinical applications and industrial microbiological control solutions for the food, biopharmaceutical, and cosmetic industries; veterinary diagnostic laboratories; and blood banks. bioMerieux also provides solutions for the enumeration of bacterial flora, which indicate the quality of food products. The company distributes its products directly and through a network of distributors across the world. bioMerieux is headquartered in Marcy l’Etoile, France.

 Gain a 360-degree view of bioMerieux SA and make more informed decisions for your business Gain a 360-degree view of bioMerieux SA and make more informed decisions for your business Find out more
Headquarters France
Address 376, Chemin De L'Orme, Craponne, Rhone Alpes, 69280
Website www.biomerieux.fr
Telephone 33 4 78872000
No of Employees 13,842
Industry Medical Equipment
Ticker Symbol & Exchange BIM (EPA)
Revenue (2022) $3.8B 6.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -24.8% (2022 vs 2021)
Market Cap* $12.9B
Net Profit Margin (2022) XYZ -29.2% (2022 vs 2021)
* As of and is in US$
View bioMerieux SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

bioMerieux SA premium industry data and analytics

140+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

50+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on bioMerieux SA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Microbiology: Training TEMPO
WASPLab Quality Management VIDAS
Automated Microbiology Specimen Processing Instrument Lab Organization Services VIDAS D-Dimer Exclusion
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand bioMerieux SA portfolio and identify potential areas for collaboration Understand bioMerieux SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Financing Agreements In October, the company invested GBP70 million in Oxford Nanopore.
2023 New Products/Services In May, the company received from the US FDA CLIA-waiver for the Biofire, Spotfire, Respiratory (R) and Panel Mini
2023 Contracts/Agreements In April, the company and Oxford Nanopore Technologies entered into a partnership to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters bioMerieux SA F. Hoffmann-La Roche Ltd Thermo Fisher Scientific Inc Abbott Laboratories Danaher Corp
Headquarters France Switzerland United States of America United States of America United States of America
City Craponne Basel Waltham Abbott Park Washington
State/Province Rhone Alpes - Massachusetts Illinois WashingtonD.C.
No. of Employees 13,842 103,613 130,000 115,000 79,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Alexandre Merieux Chairman Executive Board 2017 49
Pierre Boulud Chief Executive Officer Senior Management 2023 -
Mark Miller Executive Vice President; Chief Medical Officer Senior Management - -
Guillaume Bouhours Chief Financial Officer; Executive Vice President - Purchasing & Information Systems Senior Management 2018 -
Yasha Mitrotti Executive Vice President - Industrial Microbiology Senior Management - -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into bioMerieux SA key executives to enhance your sales strategy Gain insight into bioMerieux SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward